ES2002128A6 - Recombinant virus. - Google Patents

Recombinant virus.

Info

Publication number
ES2002128A6
ES2002128A6 ES8601549A ES8601549A ES2002128A6 ES 2002128 A6 ES2002128 A6 ES 2002128A6 ES 8601549 A ES8601549 A ES 8601549A ES 8601549 A ES8601549 A ES 8601549A ES 2002128 A6 ES2002128 A6 ES 2002128A6
Authority
ES
Spain
Prior art keywords
virtually
recombinant virus
injured
viruses
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8601549A
Other languages
Spanish (es)
Inventor
Christopher Joh Langford
John Edwards Sterling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Original Assignee
Walter and Eliza Hall Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter and Eliza Hall Institute of Medical Research filed Critical Walter and Eliza Hall Institute of Medical Research
Publication of ES2002128A6 publication Critical patent/ES2002128A6/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

UN PROCEDIMIENTO PARA LA PRODUCCION DE UN VIRUS RECOMBINANTE, TAL COMO VIRUS DE VIRUELA VACUNA RECOMBINANTE, QUE INCLUYE UNA SECUENCIA DE CODIFICACION PARA UN POLIPEPTIDO HIBRIDO QUE COMPRENDE AL MENOS UN SEGMENTO DE POLIPEPTIDO INMUNOGENICO QUE ES AJENO PARA EL VIRUS O PARA CELULAS INFECTADAS CON VIRUS EN ASOCIACION CON UN SEGMENTO DE POLIPEPTIDO DE SUPERFICIE O ASOCIADO A MEMBRANA PARA SITUAR AL POLIPEPTIDO HIBRIDO SOBRE O JUNTO A LA SUPERFICIE DE CELULAS INFECTADAS POR VIRUS.A PROCEDURE FOR THE PRODUCTION OF A RECOMBINANT VIRUS, SUCH AS VIRUS VIRUSES, RECOMBINANT VACCINE, WHICH INCLUDES A CODING SEQUENCE FOR A HYBRID POLYPEPTIDE, INCLUDING AT LEAST ONE VIRTUALLY INJURED FOR THE VIRTUALLY INJURED FOR THE VIRTUALLY VIRGIN-FREE ASSOCIATION WITH A SURFACE POLYPEPTIDE SEGMENT OR MEMBRANE ASSOCIATED TO LOCATE THE HYBRID POLYPEPTIDE ON OR NEXT TO THE SURFACE OF CELLS INFECTED BY VIRUSES.

ES8601549A 1985-08-29 1986-08-29 Recombinant virus. Expired ES2002128A6 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPH219885 1985-08-29

Publications (1)

Publication Number Publication Date
ES2002128A6 true ES2002128A6 (en) 1988-07-16

Family

ID=3771250

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8601549A Expired ES2002128A6 (en) 1985-08-29 1986-08-29 Recombinant virus.

Country Status (11)

Country Link
EP (1) EP0244427A4 (en)
JP (1) JPS63500637A (en)
KR (1) KR880700073A (en)
AU (1) AU594087B2 (en)
DK (1) DK219187D0 (en)
ES (1) ES2002128A6 (en)
FI (1) FI871885A0 (en)
IL (1) IL79880A0 (en)
NZ (1) NZ217400A (en)
WO (1) WO1987001386A1 (en)
ZA (1) ZA866582B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182211A (en) * 1987-08-07 1993-01-26 Institut Pasteur Plasmid vectors encoding a protein of a picornavirus
AU626288B2 (en) * 1988-02-05 1992-07-30 Commonwealth Scientific And Industrial Research Organisation Gene expression system (particularly for rotavirus vp7 protein) involving a foreign signal peptide and optionally a transmembrane anchor sequence
FR2663228A2 (en) * 1989-09-29 1991-12-20 Agronomique Inst Nat Rech Immunising composition against Newcastle disease and method of preparation
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
ES2431963T3 (en) 2002-07-05 2013-11-28 Folia Biotech Inc. Adjuvant Viral Particle

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2442271A1 (en) * 1978-11-27 1980-06-20 Pasteur Institut VECTOR FOR THE INSERTION OF A PROKARYOTE OR EUKARYOTE GENE, AND EXCRETION OF THE EXPRESSED PROTEIN
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
AU570940B2 (en) * 1982-11-30 1988-03-31 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Process for producing poxvirus recombinants for expression offoreign genes
AU569722B2 (en) * 1983-01-28 1988-02-18 Saramane Pty Ltd Expression of plasmodium falciparum polypeptides from cloned cdna
EP0162738A1 (en) * 1984-04-09 1985-11-27 MOLECULAR GENETICS RESEARCH & DEVELOPMENT LIMITED PARTNERSHIP Production of pseudorabies virus subunit vaccines
FR2563434B1 (en) * 1984-04-25 1986-07-25 Transgene Sa Rabies vaccine and process for its preparation

Also Published As

Publication number Publication date
DK219187A (en) 1987-04-29
EP0244427A1 (en) 1987-11-11
FI871885L (en) 1987-04-29
AU6370186A (en) 1987-03-24
EP0244427A4 (en) 1989-04-27
KR880700073A (en) 1988-02-15
IL79880A0 (en) 1986-11-30
WO1987001386A1 (en) 1987-03-12
FI871885A7 (en) 1987-04-29
JPS63500637A (en) 1988-03-10
FI871885A0 (en) 1987-04-29
DK219187D0 (en) 1987-04-29
AU594087B2 (en) 1990-03-01
NZ217400A (en) 1989-09-27
ZA866582B (en) 1987-04-29

Similar Documents

Publication Publication Date Title
AR248045A1 (en) Recombinant avipox virus
ES2166749T3 (en) NANBV DIAGNOSTICS: USEFUL POLINUCLEOTIDES TO DISCRIMINATE HEPATITIS VIRUSES.
ES2031079T3 (en) HARDENABLE MIXTURES, CONTAINING N-SULFONYLAMI-NOSULFONIUM SALTS AS CATIONALLY EFFECTIVE CATALYSTS.
AR003425A1 (en) RECOMBINANT MAPACHE POXVIRUS, VACCINE FOR USE IN CATS AND USE OF POXVIRUS TO PREPARE A VACCINE USEFUL TO AVOID OR DECREASE THE DISEASE CAUSED BY THE FELINE IMMUNODEFICIENCY VIRUS (IVF)
DE3683688D1 (en) VACCINE FOR THE GENERATION OF AN IMMUNOGENIC T-CELL REPLY PROTECTING A VIRUS.
ES535554A0 (en) PROCEDURE FOR PREPARING A VACCINE INCLUDING A TRUNCATED DERIVATIVE, FREE OF A MEMBRANE OF A TYPE FIXED TO A MEMBRANE THAT HAS EXPOSED ANTIGENIC DETERMINANTS.
ES8201006A1 (en) Product enriched by alpha-lactalbumine, its production starting from lactoserum and applications of this product.
ES2006925A6 (en) Polypeptides that elicit antibodies against AIDS virus.
ES2134197T3 (en) VACCINES AGAINST HERPES SIMPLEX VP16 VIRUSES.
ES2127294T3 (en) VACCINES OF ANTI-FELINE IMMUNODEFICIENCY VIRUSES (IVF).
FI963717A7 (en) New mutated viruses, antiviral compounds and new methods for making vaccines
ES2057339T3 (en) MEDICATION FOR APPLICATION BY SUBCUTANEOUS OR INTRAMUSCULAR ROUTE CONTAINING POLYPEPTIDES.
ES2038689T3 (en) PROCEDURE FOR THE CULTIVATION OF INFECTIOUS RHYTHNOTRACHEITIS PAVA VIRUSES AND A VACCINE PREPARED FROM VIRUSES SO OBTAINED.
ES524942A0 (en) PROCEDURE FOR THE PREPARATION OF A RECOMBINANT PLASMID INSERTED WITH THE HEPATITIS B VIRUS GENE.
ES2002128A6 (en) Recombinant virus.
ES556256A0 (en) A METHOD FOR PREPARING A VACCINE AGAINST THE EQUINE INFLUENZA VIRUS.
ES2038650T3 (en) PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION INCLUDING 3'-DEOXYTIMIDIN-2'-ENO- (3'-DESOXI-2 ', 3'-DIDESHIDROTIMIDINA) TO TREAT PATIENTS INFECTED WITH RETROVIRUS.
DK0909323T3 (en) Helicobacter pylori bacterioferritin
ES461415A2 (en) PROCEDURE FOR THE PREPARATION OF CELLULAR VACCINES.
ES8706700A1 (en) PROCEDURE FOR PREPARING A CEPHALOSPORIN DERIVATIVE.
MX2022001028A (en) AFRICAN SWINE FEVER VACCINE.
ES2058100T3 (en) COMBINED VACCINE.
ES2054230T3 (en) A PROCESS FOR THE PREPARATION OF AN ATTENUATED ENTEROVIRUS OR RHINOVIRUS.
ES2023656B3 (en) MONOAZOIC COMPOUND REACTIVE WITH FIBER, WHICH HAS AMINO-1-NAFTIL-SULPHONIC ACID 7-SUBSTITUTED AS A COPULATION COMPONENT.
ES2022118B3 (en) A PROCEDURE FOR PRODUCING CATALYSTS.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20000503